NCT01977274

Brief Summary

Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable ovarian-cancer

Timeline
114mo left

Started Dec 2013

Longer than P75 for not_applicable ovarian-cancer

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress58%
Dec 2013Dec 2035

First Submitted

Initial submission to the registry

October 30, 2013

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 6, 2013

Completed
25 days until next milestone

Study Start

First participant enrolled

December 1, 2013

Completed
20 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2033

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2035

Last Updated

March 31, 2026

Status Verified

March 1, 2026

Enrollment Period

20 years

First QC Date

October 30, 2013

Last Update Submit

March 30, 2026

Conditions

Ovarian CancerEndometrium CancerCervix Cancer

Keywords

ovarian, endometrium, cervix cancer

Outcome Measures

Primary Outcomes (1)

  • molecular alteration in gynecological cancer

    gene expression level

    average of 4 weeks after diagnosis

Secondary Outcomes (1)

  • relation between molecular alteration and clinical and histological characteristics

    up to 10 years

Study Arms (1)

gynecological cancer

EXPERIMENTAL

blood and tumor samples

Other: gynecological cancer

Interventions

gynecological cancerOTHER

blood and tumor samples

gynecological cancer

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • gynecological cancer suspicion
  • age \> 18
  • signed informed consent

You may not qualify if:

  • \- emergency

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut Paoli Calmettes

Marseille, 13 009, France

Location

Related Links

MeSH Terms

Conditions

Ovarian NeoplasmsEndometrial NeoplasmsUterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal DisordersUterine NeoplasmsUterine DiseasesUterine Cervical Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2013

First Posted

November 6, 2013

Study Start

December 1, 2013

Primary Completion (Estimated)

December 1, 2033

Study Completion (Estimated)

December 1, 2035

Last Updated

March 31, 2026

Record last verified: 2026-03

Locations

FR(1)